NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Taiho Oncology, Inc.